Evaluation of cyclophosphamide (NSC-26271) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the treatment of patients with inoperable or disseminated lung cancer.
Forty-eight patients with nonlocalized bronchogenic carcinoma were randomly selected and treated with either 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or cyclophosphamide (or both). Five of the 48 patients (three who had received BCNU and two who had received cyclophosphamide) responded to initial treatment. Crossover treatment with the alternate drug after unsuccessful treatment with the initial drug resulted in no additional responses. Toxic effects included gastrointestinal upset and myelosuppression and, in general, were acceptable. There was one death after a course of BCNU that was attributable to the myelosuppressive effects of this agent. The medain survival time of the patients who died after treatment was 18 weeks, and the mean survival time was 15 weeks. Survival times were virtually the same for both treatment groups.
Ahmann
D L
DL
Mayo Clinic and Mayo Foundation, Rochester, MN, USA.
Carr
D T
DT
Coles
D T
DT
Hahn
R G
RG
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use* / Q000633:toxicity; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D002330:Carmustine / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D045744:Cell Line, Tumor; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008495:Medical Oncology / Q000379:methods; D009362:Neoplasm Metastasis; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome
D003520:Cyclophosphamide; D002330:Carmustine